Borderline ovarian tumors and extended patient follow-up: An individual institution's experience

Journal of Surgical Oncology

Volumn 101, Issue 1, 2010, Pages 18-21

  Rettenmaier, Mark A ^a   Lopez, Katrina ^b   Abaid, Lisa N ^a   Brown III, John V ^a   Micha, John P ^a   Goldstein, Bram H ^a  

^a Gynecologic Oncology Associates   (United States)

^b Women's Cancer Research Foundation   (United States)

Author keywords

Borderline tumors of the ovary; Gynecologic oncology; Surveillance; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BORDERLINE TUMOR OF THE OVARY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PHYSICAL EXAMINATION; PHYSICIAN; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 74049137846     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21416     Document Type: Article

References (35)

1. Prat J: Ovarian tumors of borderline malignancy (tumors of low malignant potential): A critical appraisal. Adv Anat Pathol 1999; 6:247-274.
2. Trimble CL, Trimble EL: Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1994;55:S52-S61.
3. Sherman ME, Mink PJ, Curtis R: Survival among women with borderline ovarian tumors and ovarian carcinoma: A population-based analysis. Cancer 2004;100:1045-1052.
4. Riman T, Dickman PW, Nilsson S: Risk factors for epithelial borderline ovarian tumors: Results of a Swedish case-control study. Gynecol Oncol 2001;83:575-585.
5. Barnhill DR, Kurman RJ, Brady MF, et al.: Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: A Gynecologic Oncology Group Study. J Clin Oncol 1995;13:2752-2756.
6. Camatte S, Morice P, Thoury A, et al.: Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: Analysis of a continuous series of 101 cases. Eur J Cancer 2004;40:1842-1849.
7. Kaern J, Trope CG, Abeler VM: A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993;71:1810-1820.
8. Akeson M, Zetterqvist BM, Dahllof K, et al.: Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer 2008;18:453-459.
9. Suh-Burgmann E: Long term outcomes following conservative surgery for borderline tumors or the ovary: A large population based-study. Gynecol Oncol 2006;103:841-847.
10. Rao GG, Skinner EN, Gehrig PA, et al.: Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 2005; 98:263-266.
11. Seidman JD, Kurman RJ: Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20:1331-1345.
12. Longacre TA, McKenney JK, Tazelaar HD, et al.: Ovarian serous tumors of low malignant potential (borderline tumors) outcome-based study of 276 patients with long-term follow-up. Am J Surg Pathol 2005;29:707-723.
13. Kurman RJ, Trimble CL: The behavior of serous low malignant potential: Are they ever malignant? Int J Gynecol Pathol 1993; 12:120-127.
14. Trimble CL, Kosary C, Trimble EL: Long-term survival and patterns of care in Women with ovarian tumors of low malignant potential. Gynecol Oncol 2002;86:34-37.
15. Cheng B, Wan X, Qian X, et al.: Results of conservative surgery for recurrent borderline ovarian tumors. Eur J Gynaecol Oncol 2009;30:75-78.
16. Fauvet R, Poncelet C, Boccara J, et al.: Fertility after conservative treatment for borderline tumours: A French multicenter study. Fertil Steril 2005;83:284.
17. Fadare O: Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Int J Gynecol Cancer 2009;19:103-108.
18. Zanetta G, Rota S, Chiari S, et al.: Behavior of borderline tumors with particular interest to persistence, recurrence and progression to invasive carcinoma: A prospective study. J Clin Oncol 2001; 19:2658-2664.
19. Crispens MA, Bodurka D, Deavers M, et al.: Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99:3-10.
20. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al.: The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008;108:276-281.
21. Pinto MM, Bernstein LH, Brogan DA, et al.: Measurement of CA125, carcinoembryonic antigen, and alpha-fetoprotein in ovarian cyst fluid: Diagnostic adjunct to cytology. Diagn Cytopathol 1990;6:160-163.
22. Hart WR: Mucinous tumors of the ovary: A review. Int J Gynecol Pathol 2005;24:4-25.
23. Rodríguez IM, Prat J: Mucinous tumors of the ovary: A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002;26:139-152.
24. Piura B, Dganis R, Blicksteins I: Epithelial ovarian tumors of borderline malignancy: A study of 50 cases. Int J Gynecol Cancer 1992;2:189-197.
25. Deavers MT, Gershenson DM, Tortolero-Luna G, et al.: Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: A study of 99 advanced stage cases. Am J Surg Pathol 2002;26:1129-1141.
26. Nikrui N: Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol Oncol 1981;12:107-119.
27. Rao GG, Skinner E, Gehrig PA, et al.: Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 2004;104:261-266.
28. Park JY, Kim DY, Kim JH, et al.: Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol 2009;113:75-82.
29. Fauvet R, Boccara J, Dufournet C, et al.: Restaging surgery for women with borderline ovarian tumors: Results of a French multicenter study. Cancer 2004;100:1145-1151.
30. Norris HJ: Proliferative endometrioid tumors and endometrioid tumors of low malignant potential of the ovary. Int J Gynecol Pathol 1993;12:134-140.
31. Cadron I, Leunen K, Van Gorp T, et al.: Management of borderline ovarian neoplasms. J Clin Oncol 2007;25:2928-2937.
32. Morice P, Camatte S, Rey A, et al.: Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003;14:592-598.
33. Yazigi R, Munoz AK, Sandstad J, et al.: Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential. Eur J Gynaecol Oncol 1991;12:451-455.
34. Marcickiewicz J, Brannstrom M: Fertility preserving surgical treatment of borderline ovarian tumour: Long-term consequence for fertility and recurrence. Acta Obstet Gynecol Scand 2006; 85:1496-1500.
35. Gershenson DM: Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002;16:513-527.